Matt Kaeberlein

Impact

Matt Kaeberlein is a biogerontologist whose research has focused on biological mechanisms of aging with the goal of translational interventions that extend healthspan. After a PhD at MIT (2002) and postdoctoral work at the University of Washington, he joined the UW faculty, where he was the founding director of the Healthy Aging and Longevity Research Institute, director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging and director of an aging-biology training programme; he has published more than 200 papers and is a fellow of AAAS, the American Aging Association and the Gerontological Society of America. He is founder and co-director of the Dog Aging Project, a research project on aging in companion dogs. In 2023 he co-founded Optispan, a Seattle healthspan-medicine company, and led it as CEO until April 2026, when he announced he was no longer with the company and was considering his next step. He also communicates longevity science to the public through podcast, video and social-media channels.

Metrics

• 68,000 subscribers on YouTube as of 2026-09-23 source ↗

Research output

421 works · 34,375 citations · h-index 81 OpenAlex ↗

Selected publications

• Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase ↗ 2000 · 3,533 citations
• The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms ↗ 1999 · 2,287 citations
• mTOR is a key modulator of ageing and age-related disease ↗ 2013 · 1,729 citations
• Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients ↗ 2005 · 1,318 citations
• Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration ↗ 2002 · 1,074 citations

Research funding

46 NIH awards · USD 24M total NIH RePORTER ↗

• Developing the Privately Owned Companion Dog as a Model for Alzheimers Disease National Institute on Aging · 2021 · USD 1M
• Project 4: Determining the ability of rapamycin to improve lifespan and healthspan in companion dogs National Institute on Aging · 2022 · USD 1M
• Project 4: Determining the ability of rapamycin to improve lifespan and healthspan in companion dogs National Institute on Aging · 2018 · USD 1M
• Project 4: Determining the ability of rapamycin to improve lifespan and healthspan in companion dogs National Institute on Aging · 2020 · USD 1M
• Project 4: Determining the ability of rapamycin to improve lifespan and healthspan in companion dogs National Institute on Aging · 2019 · USD 1M

Links

Research fields

Associated labs